Core Viewpoint - Changchun Gaoxin (000661.SZ) has repurchased a total of 3,894,517 shares, representing 0.95% of its total share capital, through a dedicated repurchase account as of September 30, 2025 [1] Summary by Category - **Share Repurchase Details** - The company conducted the share repurchase through centralized bidding transactions [1] - The highest transaction price was 112.25 CNY per share, while the lowest was 84.00 CNY per share [1] - The total transaction amount reached 399,999,400.76 CNY, including transaction fees [1]

Core Viewpoint - A new wave of pharmaceutical companies is applying for listings on the Hong Kong Stock Exchange (HKEX), with 11 companies submitting applications in a two-day period, indicating a significant uptick in market activity [1][3]. Group 1: Listing Activity - Approximately 25 pharmaceutical companies have submitted listing applications to HKEX since September, with a notable concentration of 11 applications on September 29-30 [3]. - Companies such as Sichuan Good Doctor Cloud Medical Technology Group and Annoroad Gene Technology are among those applying, with some indicating they are unprofitable biotech firms under the HKEX Chapter 18A rules [1][3]. - The trend of "A+H" dual listings is emerging, with several companies already listed on A-shares also seeking to list on HKEX, enhancing their financing capabilities [5][6]. Group 2: Market Drivers - The HKEX's 18A listing rules, introduced in 2018, have created a pathway for unprofitable biotech companies to go public, while the "Tech Company Fast Track" launched in 2025 further streamlines the listing process for tech firms [4]. - Increased demand for healthcare services due to population aging and accelerated regulatory approvals from domestic drug monitoring agencies are contributing to a favorable environment for pharmaceutical companies [4]. Group 3: Financial Performance - Many of the companies applying for listings are currently unprofitable, with significant losses reported. For instance, Meikang Aote and its subsidiary Blue Nancheng reported losses of approximately 195 million yuan and 112 million yuan, respectively, in recent financial periods [9][10]. - The trend of unprofitable companies seeking listings under the 18A rules highlights the role of HKEX as an "innovation incubator" for the biotech sector [10]. Group 4: Future Implications - The rise of "A+H" listings is expected to reshape the competitive landscape of the domestic biotech industry, potentially accelerating industry consolidation and enhancing the market position of well-capitalized firms [7]. - Increased capital influx is anticipated to boost the development of innovative drugs and technologies, thereby improving overall industry innovation efficiency [7].

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Baike Biotechnology Co., Ltd., received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its adsorbed acellular DTPa-Hib combined vaccine [1] Group 1 - The approved Hib vaccine is in a lyophilized form, which, when used in conjunction with the liquid form of the DTPa vaccine, reduces the number of injections required [1] - This combination aims to improve vaccination compliance among infants and young children [1]

Core Viewpoint - Changchun High-tech announced that Changchun Baike Biotechnology Co., Ltd. received the clinical trial approval notice from the National Medical Products Administration for its combined vaccine against whooping cough, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b, indicating progress in vaccine development and potential market impact [1] Group 1 - The combined vaccine aims to reduce the number of doses required and improve vaccination rates, which is a significant advantage in public health [1] - The vaccine is currently in the clinical trial phase, highlighting ongoing research and development efforts in the biotechnology sector [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-133 长春高新技术产业（集团）股份有限公司 关于子公司吸附无细胞百白破 b 型流感嗜血杆菌联合疫苗 受理号：CXSL2500582 通知书编号：2025LP02637 药品名称：吸附无细胞百白破 b 型流感嗜血杆菌联合疫苗 结论：建议批准开展用于预防百日咳、白喉、破伤风和 b 型流感嗜血杆菌引起 的侵袭性感染（包括脑膜炎、肺炎、败血症、蜂窝组织炎、关节炎、会厌炎等）的 临床试验。 批准日期：2025 年 10 月 9 日 二、吸附无细胞百白破 b 型流感嗜血杆菌联合疫苗的简介 联合疫苗具有"一剂多防"的优势，可减少接种次数、降低接种成本，提升疫 苗接种覆盖率。因其符合公共卫生需求和免疫接种的发展趋势，正成为国内疫苗发 展的重要方向。 本次百克生物获批临床的吸附无细胞百白破 b 型流感嗜血杆菌联合疫苗（以下 简称"百白破-Hib 联合疫苗"）是一种可以同时预防百日咳、白喉、破伤风以及 b 型流感嗜血杆菌的疫苗。接种对象为 2 月龄及以上婴幼儿，接种后可刺激机体产生 免疫应答，用于预防百日咳、白喉、破伤风和 b 型流感嗜血杆菌引起的侵袭性感染。 临 ...

Core Viewpoint - Changchun High-tech's subsidiary, Baike Biological, has received approval from the National Medical Products Administration for clinical trials of an adsorbed acellular combined vaccine for whooping cough, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b [1] Group 1 - The approved vaccine aims to prevent infections caused by whooping cough, diphtheria, tetanus, and Haemophilus influenzae type b [1] - Currently, there are no approved adsorbed acellular combined vaccines from domestic manufacturers in the market [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Baike Biological, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its acellular combined vaccine for whooping cough, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b [1] Group 1: Product Development - The vaccine is intended to prevent whooping cough, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b [1] - Baike Biological's acellular combined vaccine (three-component) and lyophilized Haemophilus influenzae type b conjugate vaccine (Hib vaccine) are the foundation and core of the combined vaccine [1] Group 2: Business Impact - The approval will help enhance the company's combined vaccine research and development pipeline and optimize its product structure [1] - This development is expected to create new growth points for the company's performance [1] - However, there is uncertainty regarding the subsequent clinical trial process, and it will not have a significant impact on the company's recent performance [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-132 长春高新技术产业（集团）股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于2024年 11月14日召开了第十一届董事会第六次会议，审议通过了《关于公司回购股份 方案的议案》，同意公司使用自有资金及金融机构股票回购专项贷款资金以集 中竞价交易方式回购部分公司已在境内发行的人民币普通股（A股）股票，全 部用于后续实施公司及子公司核心团队股权激励或员工持股计划。拟用于回购 资金总额不低于人民币3亿元（含）、不超过人民币5亿元（含），回购价格不 超过人民币160.00元/股。具体回购股份数量以回购期限届满时实际回购的股份 数量为准。 上述内容详见公司于2024年11月16日、2024年11月21日在《中国证券报》 《证券时报》《上海证券报》《经济参考报》及巨潮资讯网（http://www.cnin fo.com.cn）上分别披露的《关于公司回购股份方案暨取得金融机构股票回购专 项贷款的公告》（公告编号 ...

Core Points - The Bioeconomy Index (970038) closed at 2386.01 points, up 0.61%, with a trading volume of 28.528 billion yuan and a turnover rate of 1.76% [1] - Among the index constituents, 32 stocks rose while 18 fell, with Deep Technology leading the gainers at 10.01% and Xinlitai leading the decliners at 3.96% [1] Index Constituents Summary - Major constituents of the Bioeconomy Index include: - Mindray Medical (13.81% weight) at 248.24 yuan, up 1.04% [1] - Changchun High-tech (5.41% weight) at 129.25 yuan, down 0.58% [1] - Kanglong Chemical (4.66% weight) at 35.30 yuan, down 1.26% [1] - Deep Technology (4.08% weight) at 30.66 yuan, up 10.01% [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 224 million yuan from main funds, while retail investors saw a net inflow of 207 million yuan [3] - Notable capital flows include: - Deep Technology with a main fund net inflow of 28.4 million yuan [3] - Mindray Medical with a main fund net inflow of 80.8494 million yuan [3] - Other companies like Boteng Co. and Zhifei Biological also showed varying net inflows and outflows [3]

Core Viewpoint - Changchun High-tech aims to enhance its international presence and innovation capabilities by issuing H-shares for listing on the Hong Kong Stock Exchange, with funds primarily allocated for R&D, clinical trials, and international market expansion [1][3]. Fundraising Purpose - The funds raised will be used for two main directions: advancing the innovation pipeline, including clinical trials and regulatory affairs, and establishing a commercial team overseas for global collaboration and market expansion [1][3]. Financial Performance - Since 2022, Changchun High-tech's stock price has experienced significant fluctuations due to rumors surrounding the centralized procurement of growth hormones, culminating in a decline in both revenue and net profit for the first time in nearly two decades in 2024 [3]. Innovation Pipeline - The company has over 40 projects in clinical stages or IND applications, including 11 Class I innovative biological agents and 4 Class I innovative chemical drugs, focusing on endocrine and metabolic diseases, women's health, immune and respiratory systems, and oncology [3][4]. Key Products - GenSci134, a long-acting growth hormone, is currently undergoing Phase I clinical trials for adult growth hormone deficiency and has received IND approval for pediatric growth hormone deficiency and idiopathic short stature [4][5]. - GenSci074, an NK3R antagonist for treating vasomotor symptoms in menopausal women, is in Phase II clinical trials, with competition from other drugs in the same category [7][8]. Oncology Pipeline - The company is developing several innovative drugs targeting prostate, breast, and ovarian cancers, including GenSci139, GenSci140, and GenSci143, which are expected to enter Phase I clinical trials by Q4 2025 [10][11]. - GenSci139 targets low-expressing HER2 tumors and faces a competitive landscape with existing ADC therapies [11][12]. - GenSci140 aims to expand patient coverage for FRα-positive cancers and is the only FRα dual-target ADC in development in China [13][14]. - GenSci143 targets both B7-H3 and PSMA antigens, potentially offering broader patient coverage but is still in early development stages [15]. Other Therapeutic Areas - GenSci098 is a TSHR antagonist for treating thyroid-associated ophthalmopathy, indicating the company's diversification into immune and respiratory diseases [16].